Accelr8 and BD Sign Research and Licensing Option Agreement for Commercializing Accelr8's...

Accelr8 and BD Sign Research and Licensing Option Agreement for Commercializing Accelr8's BACcel(TM) Rapid Diagnostics Technology

DENVER--(Business Wire)--
Accelr8 Technology Corporation (AMEX: AXK) announced today that it
has signed an agreement with BD (Becton, Dickinson and Company) with
respect to Accelr8's BACcel(TM) rapid pathogen diagnostics platform.
Under the agreement, BD will fund a research program at Accelr8
through September 30, 2009. The research program includes mutually
agreed milestones to support BD's product development planning. BD has
the option, during or at the conclusion of the research program, to
exclusively license Accelr8's intellectual property in the field of
infectious diseases diagnostics. Accelr8 would retain the right to
commercialize its technology for other applications.

The option, if exercised by BD, requires BD to pay an initial fee,
as well as running royalties on covered products. The license further
contains certain diligence requirements for BD to develop and
commercialize such products. Under the license, BD will fund and
conduct all product development, manufacturing, and marketing.

This agreement follows a standstill agreement signed in December
2007. Since signing that agreement, Accelr8 placed research systems
into two premier research institutions, Denver Health Medical Canter
and Washington University in St. Louis (Barnes-Jewish Hospital). The
two research centers have been conducting independent studies that
confirm and extend Accelr8's internal research that the company
presented at two leading scientific and medical conferences in 2007.

"We are very pleased to enter into a formal relationship with BD
to develop what Accelr8 believes will be the next major advance in
infectious diseases diagnostics," said David Howson, Accelr8's
president. "As industry leader in clinical microbiology, BD brings the
tremendous resources and experience needed to introduce this
potentially game-changing innovation to hospitals globally.

"We also believe that this relationship offers our shareholders
the best opportunity by avoiding the distraction, risk, and dilution
of further fundraising," Howson continued. "The relationship assures
that we can continue to focus on the core science and technology and
collaborate with leading research institutions to build the case for
clinical acceptance."

About Accelr8

Accelr8 Technology Corporation (www.accelr8.com) is a developer of
innovative materials and instrumentation for advanced applications in
medical instrumentation, basic research, drug discovery, and
bio-detection. Accelr8 is developing a rapid pathogen analysis and
diagnostic platform, the BACcel(TM) system, based on its innovative
surface coatings, assay processing, and detection technologies. In
addition, Accelr8 licenses certain of its proprietary technology for
use in applications outside of Accelr8's own products.

Certain statements in this news release may be "forward-looking
statements" within the meaning of Section 27A of the Securities Act of
1933, as amended, and Section 21E of the Securities Exchange Act of
1934, as amended. Statements regarding future prospects and
developments are based upon current expectations and involve certain
risks and uncertainties that could cause actual results and
developments to differ materially from the forward-looking statement,
including those detailed in the company's filings with the Securities
and Exchange Commission. Accelr8 does not undertake an obligation to
publicly update or revise any forward-looking statements, whether as a
result of new information or future events.

Metzger Associates for Accelr8 Technology Corporation
John Metzger, 303-786-7000, ext. 2202
john@metzger.com
or
Accelr8 Technology Corporation
Tom Geimer, 303-863-8088
tom.geimer@accelr8.com

Copyright Business Wire 2008